BWAY - BrainsWay Ltd.
HWG Holdings LP purchased a new stake in Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 253,050 shares of the company's stock, valued at approximately $3,340,000. HWG Holdings LP owned 0.63% of Brainsway at
CapsoVision (NASDAQ: CV - Get Free Report) and Brainsway (NASDAQ: BWAY - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Analyst Ratings This is a summary of current recommendations
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report)'s share price gapped down prior to trading on Tuesday. The stock had previously closed at $13.57, but opened at $13.14. Brainsway shares last traded at $13.4220, with a volume of 36,886 shares changing hands. Analyst Upgrades and Downgrades A number of equities analysts recently commented
Peer-reviewed pilot study shows 83.3% response rate and 50% remission rate in depressive symptoms, alongside measurable neurophysiological changes in brain activity and connectivity
Brainsway (NASDAQ: BWAY - Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Profitability This table compares Brainsway and Green
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY, a steady 75% gross margin, and expects FY-2026 revenue of $66–68M with adjusted EBITDA growth of 86–100%. Multi-year leasing, accelerated protocols, and expanded provider access are reducing TMS adoption barriers, supporting higher utilization and stickier customer relationships.
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $17.50 and last traded at $17.50, with a volume of 700 shares. The stock had previously closed at $16.51. Wall Street Analyst Weigh In Several research firms recently
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.
HTLD, MEOH, NCNO, JD and BWAY have been added to the Zacks Rank #1 (Strong Buy) List on July 14th, 2026.
Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD), making comorbid depression one of the most common and clinically significant complications of PTSD